[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:ovarian-clear-cell-adenocarcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":49,"states":50},"Ovarian Clear Cell Adenocarcinoma",6,5,[8,16,23,29,36,42],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06065462","Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:01.910993Z","2026-05-05T02:43:27.860782Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06321484","Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer",[20],"Phase 1","2026-08-26T02:18:08.005333Z","2026-07-05T05:32:16.754624Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04104776","A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",[12],"2026-08-26T02:17:15.156099Z","2026-07-05T05:32:16.792523Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06730347","A Study of Lorigerlimab in Participants With Advanced Solid Tumors",[33],"Phase 2","2026-08-26T02:17:09.131534Z","2026-06-18T04:29:21.275392Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07690189","Study of NTB-928 in R\u002FR OC",[20],"2026-08-26T02:17:04.346841Z","2026-07-19T19:36:05.156065Z",{"nct_id":43,"title":44,"phases":45,"status":46,"updated_at":47,"content_modified":48},"NCT07718854","Sacituzumab Tirumotecan +\u002F- Pembrolizumab in I\u002FO Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer",[33],"NOT_YET_RECRUITING","2026-08-26T02:17:51.502023Z","2026-07-24T01:27:14.918587Z",[],[51,55],{"state":52,"count":53,"slug":54},"Texas",4,"texas",{"state":56,"count":57,"slug":58},"Massachusetts",3,"massachusetts"]